Serhat TUNAR -TDO- United States-based pharmaceutical company Moderna has announced approval to begin third-stage clinical trials for a potential covid-19 vaccine, called "mRNA-1273," developed in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID). The company has signed a protocol with the United States Food and Drug Administration (FDA) for the trial.
MRNA-1273 will be used as a covid-19 vaccine if Moderna is successful in phase three trials.
According to the protocol, trials will be conducted on 30 thousand healthy volunteers in the United States and vaccine trials, each of which will be 0.1 milligrams, will begin next month.
The vaccine, developed by Moderna, aims to provide immunity in the body by suppressing the enzyme called the nail protein, which allows Covid-19 to hold onto the human cell.